Aripiprazole News : GoldBamboo.com http://goldbamboo.com/ Aripiprazole News from GoldBamboo.com en-us © 2005, Gold Bamboo LLC, All Rights Reserved ABILIFY(R) (Aripiprazole) Injection For Intramuscular Use For Adults With Agitation Associated With Schizophrenia Or Bipolar Mania Now Available http://goldbamboo.com/news-a211303.html Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY(R) (aripiprazole) Injection, an injectable form of ABILIFY, for intramuscular use. ABILIFY Injection provides rapid control of agitation in adults with schizophrenia or bipolar mania at primary endpoint (2 hours). The U.S. [click link for full article] Wed, 13 Dec 2006 08:00 EST ABILIFY(R) (aripiprazole) Demonstrated Efficacy As Long-Term Maintenance Therapy In Adults With Bipolar I Disorder http://goldbamboo.com/news-a210555.html Maintenance therapy with the Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. [click link for full article] Fri, 08 Dec 2006 08:00 EST BMS And Otsuka Pharmaceutical Company Launch New Rapidly Disintegrating Oral Antipsychotic Medication Ablify And Discmelt (aripiprazole) http://goldbamboo.com/news-a194592.html Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY® DISCMELT™ (aripiprazole) Orally Disintegrating Tablets, a new oral form of the antipsychotic medication ABILIFY® (aripiprazole) that disintegrates rapidly in the mouth. The U.S. Food and Drug Administration (FDA) approved ABILIFY DISCMELT on June 7, 2006. [click link for full article] Sun, 20 Aug 2006 05:00 EST Six-Month Study Evaluated Effectiveness Of Aripiprazole And Standard Of Care In Management Of Community-Treated Patients With Schizophrenia http://goldbamboo.com/news-a182612.html The Bristol-Myers SquibbCompany (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. atypicalantipsychotic medicine, aripiprazole, demonstrated significantly greaterimprovement on the Investigator's Assessment Questionnaire (IAQ) versusstandard-of-care in a six-month, randomized, open-label, multicenter trialof more than 500 adults living with schizophrenia conducted in Europe. [click link for full article] Sun, 28 May 2006 06:00 EST 6-Month Study Evaluated Effectiveness Of Aripiprazole And Standard Of Care In Management Of Community-Treated Patients With Schizophrenia http://goldbamboo.com/news-a182668.html The Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. atypical antipsychotic medicine, aripiprazole, demonstrated significantly greater improvement on the Investigator's Assessment Questionnaire (IAQ) versus standard-of-care in a six-month, randomized, open-label, multicenter trial of more than 500 adults living with schizophrenia conducted in Europe. [click link for full article] Mon, 29 May 2006 06:00 EST